Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerd-Rüdiger Burmester

Showing results (161-170 of 171) with videos related to

Pageof 18
Sort By:
Journal of Molecular Medicine (Berlin, Germany)|March 31, 2017
Type I interferon as a biomarker in autoimmunity and viral infection: a leukocyte subset-specific analysis unveils hidden diagnostic optionsRomy Strauß, Thomas Rose, Shaun M Flint, et al.
Kidney International|June 28, 2020
Nuclear antigen-reactive CD4<sup>+</sup> T cells expand in active systemic lupus erythematosus, produce effector cytokines, and invade the kidneysDimas Abdirama, Sebastian Tesch, Anna-Sophie Grießbach, et al.
RMD Open|January 4, 2023
Type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic diseaseLeonie Maria Frommert, Amanthi Nadira Arumahandi de Silva, Jan Zernicke, et al.
Annals of the Rheumatic Diseases|February 25, 2025
Teclistamab in relapsed systemic sclerosis after autologous haematopoietic stem cell transplantationElise Siegert, Robert Biesen, Maria Dzamukova, et al.
Clinical and Experimental Rheumatology|November 30, 2020
Evolving the comprehensive management of rheumatoid arthritis: identification of unmet needs and development of practical and educational toolsGerd-Rüdiger Burmester, José María Álvaro-Gracia, Neil Betteridge, et al.
Clinical and Experimental Rheumatology|April 7, 2016
Clinical experience with the European Ankylosing Spondylitis Infliximab Cohort (EASIC): long-term extension over 7 years with focus on clinical efficacy and safetyFrank Heldmann, Xenofon Baraliakos, Uta Kiltz, et al.
The Journal of Rheumatology|September 18, 2012
Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID)Petra Roll, Eva Ostermeier, Marion Haubitz, et al.
International Journal of Rheumatic Diseases|May 9, 2024
Listening to patients, for the patients: The COVAD Study-Vision, organizational structure, and challengesMrudula Joshi, Naitica Darooka, Sreoshy Saha, et al.
Rheumatology International|October 14, 2024
Correction to: Collating the voice of people with autoimmune diseases: Methodology for the third phase of the COVAD studiesEsha Kadam, Mahnoor Javaid, Parikshit Sen, et al.
Rheumatology International|April 12, 2024
Collating the voice of people with autoimmune diseases: Methodology for the Third Phase of the COVAD StudiesEsha Kadam, Mahnoor Javaid, Parikshit Sen, et al.
Pageof 18

Showing results (161-170 of 171) with videos related to

Sort By:
Pageof 18
Journal of Molecular Medicine (Berlin, Germany)|March 31, 2017
Type I interferon as a biomarker in autoimmunity and viral infection: a leukocyte subset-specific analysis unveils hidden diagnostic optionsRomy Strauß, Thomas Rose, Shaun M Flint, et al.
Kidney International|June 28, 2020
Nuclear antigen-reactive CD4<sup>+</sup> T cells expand in active systemic lupus erythematosus, produce effector cytokines, and invade the kidneysDimas Abdirama, Sebastian Tesch, Anna-Sophie Grießbach, et al.
RMD Open|January 4, 2023
Type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic diseaseLeonie Maria Frommert, Amanthi Nadira Arumahandi de Silva, Jan Zernicke, et al.
Annals of the Rheumatic Diseases|February 25, 2025
Teclistamab in relapsed systemic sclerosis after autologous haematopoietic stem cell transplantationElise Siegert, Robert Biesen, Maria Dzamukova, et al.
Clinical and Experimental Rheumatology|November 30, 2020
Evolving the comprehensive management of rheumatoid arthritis: identification of unmet needs and development of practical and educational toolsGerd-Rüdiger Burmester, José María Álvaro-Gracia, Neil Betteridge, et al.
Clinical and Experimental Rheumatology|April 7, 2016
Clinical experience with the European Ankylosing Spondylitis Infliximab Cohort (EASIC): long-term extension over 7 years with focus on clinical efficacy and safetyFrank Heldmann, Xenofon Baraliakos, Uta Kiltz, et al.
The Journal of Rheumatology|September 18, 2012
Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID)Petra Roll, Eva Ostermeier, Marion Haubitz, et al.
International Journal of Rheumatic Diseases|May 9, 2024
Listening to patients, for the patients: The COVAD Study-Vision, organizational structure, and challengesMrudula Joshi, Naitica Darooka, Sreoshy Saha, et al.
Rheumatology International|October 14, 2024
Correction to: Collating the voice of people with autoimmune diseases: Methodology for the third phase of the COVAD studiesEsha Kadam, Mahnoor Javaid, Parikshit Sen, et al.
Rheumatology International|April 12, 2024
Collating the voice of people with autoimmune diseases: Methodology for the Third Phase of the COVAD StudiesEsha Kadam, Mahnoor Javaid, Parikshit Sen, et al.
Pageof 18